Canadian Respiratory Journal / 2017 / Article / Tab 2

Research Article

Impaired Hemorheology in Exacerbations of COPD

Table 2

Pulmonary function test results of the subjects.

Pulmonary function testControl group
( = 12)
Newly diagnosed patient groupExacerbation group
( = 16)
Before treatment
( = 13)
After treatment
( = 13)

FVC (%)97.67 ± 14.0782.23 ± 13.9788.77 ± 16.1068.5 ± 30.6 0.0050.006
FEV1 (%)99.25 ± 12.8366.69 ± 13.8 75.54 ± 20.1 64.36 ± 16.1 0.00010.0001
FEV1/FVC ratio82.58 ± 6.0463.85 ± 4.7 64.46 ± 8.6 60.93 ± 8.1 0.00010.0001
PEF (%)90.33 ± 12.0664.69 ± 16.1 70.54 ± 24.5 46.88 ± 29.3 0.00010.0001
FEF 25–75 (%)90.67 ± 20.8335.38 ± 9.4 42.08 ± 14.5 25.38 ± 16.2 0.00010.0001

Values are expressed as means ± SD (FEV1: forced expiratory volume in the first second, FVC: forced vital capacity, PEF: peak expiratory flow, and FEF 25/75: forced expiratory flow 25% to 75%). : difference between the control group, before treatment of newly diagnosed COPD, and the exacerbation group; : difference between the control group, after treatment of newly diagnosed COPD, and the exacerbation group; < 0.05: difference from control, < 0.05: difference from before treatment of COPD, and < 0.05: difference from after treatment of COPD. and are findings via ANOVA whereas other symbols are findings by comparison of two groups.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.